Takeda Pharmaceutical Limited (TAK) Return on Equity ROE from the fourth quarter 2025 to fourth quarter 2024 and annually, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Takeda Pharmaceutical Company Limited  (NYSE: TAK)

Takeda Pharmaceutical Limited's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Takeda Pharmaceutical Limited in the fourth quarter 2025?
Takeda Pharmaceutical Company Limited achieved a return on average equity (ROE) of 1.51 % in its fourth quarter 2025, which is below Takeda Pharmaceutical Limited's average return on equity, which stands at 3.46%.

ROE fell compared to the third quarter 2025, despite the net income growth of % from the third quarter 2025.

Within the Major Pharmaceutical Preparations industry 50 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 2037 to 2063.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Mar 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Mar 31 2024)
IV. Quarter
Y / Y Equity Change -11.21 % 13.02 % -11.21 % -11.21 % -
Y / Y Net Income Change -30.16 % - - - -55.09 %
Net Income (TTM) in Millions 689 986 986 986 986
Return On Equity (TTM) 1.51 % 2.1 % 2.17 % 2.1 % 2.04 %
TAK's Total Ranking # 2063 # 2037 # # #
Equity (TTM) in Millions 44,181 49,759 44,181 44,181 49,759
Seq. Equity Change -11.21 % 12.62 % 0 % -11.21 % 13.02 %
Seq. Net Income Change - - - - -

Back to TAK Management Effectiveness >> TAK's 5 Years Annual ROE >> Compare TAK ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 51
Sector # 168
Overall # 2063

Return On Equity Statistics
High Average Low
7.27 %
3.46 %
0.93 %
(Mar 31 2021)   (Mar 31 2020)





TAK Annual Return On Equity (Mar 31 2025)
2025		 (Mar 31 2024)
2024		 (Mar 31 2023)
2023		 (Mar 31 2022)
2022		 (Mar 31 2021)
2021
Total Equity in Millions 44,181 49,759 44,025 41,611 46,602
Y / Y Equity Change -11.21 % 13.02 % 5.8 % -10.71 % 6 %
Net Income in Millions 689 986 2,196 1,685 3,386
Y / Y Net Income Change -30.16 % -55.09 % 30.34 % -50.23 % 731.02 %
Return On Equity 1.56 % 1.98 % 4.99 % 4.05 % 7.27 %

Back to TAK Management Effectiveness >> TAK's 5 Years Annual ROE >> Compare TAK ROE to its Competitors




Annual Roe Comment
In 2025 ROE decreased compared to the previous year to 1.56 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TAK's' Return on Equity at Yahoo Finance
TAK's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TAK's Competitors
Subscribers only: Roe for Takeda Pharmaceutical Limited's Suppliers
Subscribers only: Return On Equity for TAK's Customers




Companies with similar Return On Equity at Mar 31 2025, within Healthcare Sector ROE
Vaso Corporation  3.93 %
Revvity Inc  3.69 %
Penumbra Inc  3.65 %
Teleflex Incorporated  3.43 %
Brightspring Health Services Inc   3.35 %
Sensus Healthcare Inc   3.34 %
Privia Health Group Inc   2.97 %
Veracyte Inc   2.83 %
Perspective Therapeutics Inc   2.73 %
Monte Rosa Therapeutics Inc   2.65 %
Talkspace Inc   2.54 %
Veru Inc   2.37 %
American Shared Hospital Services  1.80 %
Takeda Pharmaceutical Company Limited  1.56 %
Accuray Incorporated  1.46 %
Vericel Corporation  1.09 %
Keros Therapeutics Inc   0.75 %
Incyte Corporation  0.64 %
Radnet Inc   0.33 %

Date modified: 2026-07-07T13:58:33+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.